Shattuck Labs (STTK) Competitors

Arcturus Therapeutics (NASDAQ:ARCT) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Which has more risk and volatility, ARCT or STTK?

Arcturus Therapeutics has a beta of 3.41, indicating that its share price is 241% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500.

Does the MarketBeat Community favor ARCT or STTK?

Arcturus Therapeutics received 408 more outperform votes than Shattuck Labs when rated by MarketBeat users. However, 69.64% of users gave Shattuck Labs an outperform vote while only 66.32% of users gave Arcturus Therapeutics an outperform vote.

Company	Underperform	Outperform
Arcturus Therapeutics	Outperform Votes 447 66.32%	Underperform Votes 227 33.68%
Shattuck Labs	Outperform Votes 39 69.64%	Underperform Votes 17 30.36%

Do analysts prefer ARCT or STTK?

Arcturus Therapeutics presently has a consensus price target of $59.20, indicating a potential upside of 462.20%. Shattuck Labs has a consensus price target of $7.50, indicating a potential upside of 869.87%. Given Shattuck Labs' higher possible upside, analysts clearly believe Shattuck Labs is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Shattuck Labs	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.71

Which has better earnings and valuation, ARCT or STTK?

Arcturus Therapeutics has higher revenue and earnings than Shattuck Labs. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$138.39M	2.06	-$29.73M	-$3.01	-3.50
Shattuck Labs	$5.72M	6.47	-$87.30M	-$1.49	-0.52

Is ARCT or STTK more profitable?

Arcturus Therapeutics has a net margin of -36.39% compared to Shattuck Labs' net margin of -1,156.46%. Arcturus Therapeutics' return on equity of -22.39% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-36.39%	-22.39%	-14.81%
Shattuck Labs	-1,156.46%	-61.92%	-54.49%

Does the media favor ARCT or STTK?

In the previous week, Arcturus Therapeutics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 4 mentions for Arcturus Therapeutics and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.62 beat Arcturus Therapeutics' score of 0.47 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in ARCT or STTK?

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 15.3% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Arcturus Therapeutics beats Shattuck Labs on 12 of the 19 factors compared between the two stocks.